Lumicitabine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lumicitabine
Accession Number
DB14808
Description

Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 433.86
Monoisotopic: 433.1415914
Chemical Formula
C18H25ClFN3O6
Synonyms
  • ALS-008176
  • Lumicitabine

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
BNW5PQ52G1
CAS number
1445385-02-3
InChI Key
MJVKYGMNSQJLIN-KYZVSKTDSA-N
InChI
InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
IUPAC Name
[(2R,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(chloromethyl)-4-fluoro-3-[(2-methylpropanoyl)oxy]oxolan-2-yl]methyl 2-methylpropanoate
SMILES
CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O

References

General References
Not Available
ChemSpider
58171803
ChEMBL
CHEMBL3417258
ZINC
ZINC000147003908
Wikipedia
Lumicitabine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedOtherInfections, Respiratory Syncytial Virus1
2CompletedTreatmentInfections, Respiratory Syncytial Virus2
2TerminatedTreatmentRespiratory Syncytial Virus (RSV)2
2WithdrawnTreatmentMetapneumovirus1
1CompletedNot AvailableInfections, Respiratory Syncytial Virus1
1CompletedBasic ScienceInfections, Respiratory Syncytial Virus1
1CompletedOtherHealthy Volunteers1
1CompletedOtherImpaired kidney function1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentInfections, Respiratory Syncytial Virus2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.063 mg/mLALOGPS
logP2.11ALOGPS
logP2.05ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)19.22ChemAxon
pKa (Strongest Basic)3.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area120.52 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity98.79 m3·mol-1ChemAxon
Polarizability41.59 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 14:28 / Updated on February 21, 2021 18:54